Display options
Cite
Webster, J., Kauffman, T. L., Feigelson, H. S., Pawloski, P. A., Onitilo, A. A., Potosky, A. L., ... & CERGEN study team. (2013). KRAS testing and epidermal growth factor receptor inhibitor treatment for colorectal cancer in community settings. Cancer Epidemiology and Prevention Biomarkers, 22(1), 91-101.
Webster, Jennifer, et al. "KRAS testing and epidermal growth factor receptor inhibitor treatment for colorectal cancer in community settings." Cancer Epidemiology and Prevention Biomarkers 22.1 (2013): 91-101.
Copy Download .nbib Format: MLA
Share it on
Full text links
View full text

J Webster, TL Kauffman, HS Feigelson… - Cancer Epidemiology …, 2013 - AACR

KRAS testing and epidermal growth factor receptor inhibitor treatment for colorectal cancer in community settings.

community settings

Webster

GSID: yCKyzQYLCigJ

Excerpt

Background: In metastatic colorectal cancer (mCRC), mutations in the KRAS gene predict poor response to EGF receptor (EGFR) inhibitors. Clinical treatment guidelines now recommend KRAS testing if EGFR inhibitors are considered. Our study investigates the clinical uptake …

Similar articles

Cited by